Articles tagged "Malignancy"

2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Does Post-Transplant Adherence Come at a Cost?
K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
University of Minnesota, Minneapolis, MN.
Background: It is well documented that organ transplant (tx)recipients have an increased incidence of cancer including virus associated cancers like lymphoma. Our objective was to…
2016 American Transplant Congress
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.
M. Grąt,¹ J. Stypułkowski,¹ W. Patkowski,¹ K. Wronka,¹ M. Wasilewicz,² K. Grąt,³ L. Masior,¹ M. Krasnodębski,¹ Z. Lewandowski,⁴ M. Krawczyk.¹
¹Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; ²Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; ³Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; ⁴Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.
Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
2016 American Transplant Congress
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…
2016 American Transplant Congress
Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality.
S. Ajani, M. Valapour, M. Budev.
Respiratory Institute, Cleveland Clinic, Cleveland, OH.
PurposeAssess the impact of pre-transplant prostate cancer on mortality after lung transplant and the incidence of recurrence of prostate cancer after transplant.MethodsThe electronic medical records…
2016 American Transplant Congress
Recipient Outcomes in U.S. Cases of Post-Donation Living Donor Malignancy.
A. Wilk,¹ S. Taranto,¹ M. Nalesnik.³
¹United Network for Organ Sharing, Richmond, VA; ²Duke Univ Medical Center, Durham, NC; ³Univ of Pittsburgh, Pittsburgh, PA.
Background: Under current OPTN policy, living donors (LD) are required to be followed for two years (yrs) post-donation. Cases of malignancy in LD post-donation can…
2016 American Transplant Congress
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.
W. Yin.^1,2
¹Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan; ²Surgery, Dalin Tzu Chi General Hospital, Chia-I, Taiwan.
IntroductionMalignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ…
2016 American Transplant Congress
C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.
C. Blosser,¹ Y. Zhang,² T. Dhawale,³ C. Johnson,¹ P. Hendrie,³ R. Smith.²
¹Medicine, University of Washington, Seattle, WA; ²Medicine & Surgery, University of Iowa, Iowa City, IA; ³Medicine, Seattle Cancer Care Alliance, Seattle, WA.
Background: Monoclonal gammopathy of renal significance (MGRS) implies a causal relationship between clonal B cell proliferation and renal disease and is associated with high morbidity…